SOLICITATION NOTICE
A -- Highly Potent Cancer Nanotherapeutics - S10-140
- Notice Date
- 4/1/2010
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, Maryland, 21702
- ZIP Code
- 21702
- Solicitation Number
- S10-140
- Archive Date
- 5/13/2010
- Point of Contact
- Matt DeSantis, Phone: 301/228-4002, Shannon B Jackson, Phone: 301-228-4022
- E-Mail Address
-
desantisma@mail.nih.gov, jacksonshannon@mail.nih.gov
(desantisma@mail.nih.gov, jacksonshannon@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Highly Potent Cancer Nanotherapeutics E-mail questions in writing to desantisma@mail.nih.gov by 3:00 pm (ET) by April 12, 2010. The purpose of this subcontract is to identify and evaluate the potential of candidate nanotechnologies to significantly improve the therapeutic index, bioavailability, solubility, and/or pharmacokinetics of otherwise failed anti-cancer agents. Specifically, this subcontract is intended to fund nanotechnology delivery systems which will allow anti-cancer drugs which could not otherwise be delivered in free form due to their excessive toxicity, poor oral bioavailability, poor solubility in biological fluids, inappropriate pharmacokinetics, and lack of efficacy within a tolerable dose range to be re-examined as potential therapies for cancer treatment. The purpose of this subcontract is NOT to fund basic research on nanoplatform development nor is it intended to fund the new synthesis approach to failed anti-cancer compounds. If the drug can currently be administered to humans in free form and the drug-nanoparticle construct provides only an incremental improvement over the free drug, then the drug-nanoparticle construct is not of interest to NCI and SAIC-Frederick. If, however, the drug-nanoparticle construct results in a significant improvement in properties over the free drug, then NCI and SAIC-Frederick would be interested in the drug-nanoparticle construct. If the drug can not currently be administered to humans in free form and the drug-nanoparticle construct mitigates the unacceptable properties of the drug allowing the drug to be re-evaluated as an anti-cancer agent, then NCI and SAIC-Frederick would be very interested in the drug-nanoparticle construct.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF/S10-140/listing.html)
- Place of Performance
- Address: Subcontractor's site, United States
- Record
- SN02110724-W 20100403/100402000149-01e5e96e303fd592f16fa7314ffb6887 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |